Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Celebrating its 40th anniversary in 2021, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new tools and technologies, investment growth, and career opportunities. Through its cornerstone Magazine, dynamic Website, high-frequency eNewsletters, and innovative suite of multimedia, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their success. GENs breadth of editorial coverage is unrivaled, providing exclusive reporting, insight, and analysis across the life sciences from its five foundational pillars of Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing to a new, expanded focus on the emerging areas of Cancer Research, Infectious Diseases, and Artificial Intelligence. Within these areas, GEN delivers exclusive, high-quality reporting on the latest industry news; insider information on cutting-edge tools and technologies; industry-standard protocols, tutorials, and technical articles; first-looks at emerging industry collaborations and investments; reports from key scientific and industry meetings; and A-Lists, our monthly insight and analysis into the top companies, products, and movers & shakers impacting the industry today.